Mass General develops noninvasive assay to monitor treatment response in patients with metastatic prostate cancer
- Posted: October 24, 2012
Deciding the ideal treatment for patients with metastatic prostate cancer that stops responding to initial therapy could be guided by certain analyses of cancer cells isolated from the patients' blood, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. Researchers from the Massachusetts General Hospital Cancer Center in Boston, a component of the Dana-Farber Cancer Institute, established a way to isolate cancer cells from the blood of patients with prostate cancer and to measure readouts of androgen receptor signaling in each of the individual cancer cells in the blood.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.